Results 111 to 120 of about 39,467 (264)
International Brazilian Journal of Urology, 2014 Introduction This study describes the incidence and risk factors of de novo nephrolithiasis among patients with lymphoproliferative or myeloproliferative diseases who have undergone chemotherapy. Materials and Methods
Hossein S. Mirheydar +8 more
doaj +1 more source
Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment. [PDF]
Front Oncol, 2023 Symeonidis A, Germing U.
europepmc +1 more source
Bleeding and thrombosis in the myeloproliferative disorders [PDF]
Blood, 1984 Bleeding and thrombosis are major causes of morbidity and mortality in patients with myeloproliferative disorders. The significance of uncontrolled polycythemia as a risk factor for thrombosis in these patients has been established. However, the role of thrombocytosis in the pathogenesis of hemostatic complications remains controversial.
openaire +3 more sources
Intracellular lysozyme and lactoferrin in myeloproliferative disorders. [PDF]
, 1977 D Y Mason
openalex +1 more source
Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy
MedComm, Volume 6, Issue 10, October 2025.Our review focused on how specific cellular subsets crucial for igniting tumor immunity cycle, notably effector and helper T cells alongside antigen presentation cells, interact closely in both antigen‐dependent and ‐independent manners (within centered ring) adjacent to cancer cells.
Ying Peng +21 more
wiley +1 more source
Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases
Клиническая онкогематология, 2019 Background. Cerebrovascular disorders continue to be among the most common and socially significant worldwide. Among multiple reasons for circulatory disturbances special importance is attached to hemorheology and hemostasis disorders occurring also in ...
MM Tanashyan +3 more
doaj +1 more source
MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
Онкогематология, 2017 Chronic myeloid malignancies that have characteristics of both the myelodysplastic and myeloproliferative disorders allocated to myelodysplastic/myeloproliferative diseases (MDS/MPD) group in 2008 World Health Organization classification.
I. N. Subortseva, A. I. Melikyan
doaj +1 more source
Targeting the Ubiquitin–Proteasome System for Cancer
MedComm, Volume 6, Issue 10, October 2025.This figure shows the mechanism of protein degradation by ubiquitin–proteasome system. The process begins with ubiquitin activation by the E1 enzyme, forming a thioester bond between E1's cysteine residue and ubiquitin's glycine carboxyl group, powered by ATP hydrolysis.
Zhaoyun Liu +5 more
wiley +1 more source
Myeloproliferative disorders: A retrospective cohort study. [PDF]
Ann Med Surg (Lond), 2021 Mhmed Ali R, Masoud V.
europepmc +1 more source
Myeloproliferative Disorders in Dogs and Cats
Veterinary Clinics of North America: Small Animal Practice, 1981 Veterinary Clinics of North America: Small Animal Practice 11 (1981) 349-381. doi:10.1016/S0195-5616(81)50034-9 ; Received by publisher: 0000-01-01 ; Harvest Date: 2016-01-04 12:21:48 ; DOI:10.1016/S0195-5616(81)50034-9 ; Page Range: 349 ...
Associate Professor and Chief, Clinical Pathology Service, University of Florida College of Veterinary Medicine, Gainesville, Florida +2 more
openaire +4 more sources